NEOVACS WILL ATTEND THE 2016 EUROPEAN SMALLCAP ...

 PRESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE

Neovacs will attend the 2016 European Smallcap Event

April 11 & 12, 2016

Paris, March 21, 2016 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, will be pleased to meet investors during:

The 2016 European Smallcap Event

April 11 & 12, 2016 - Palais Brongniart, Paris (France)

For more details on the event: http://www.midcapevents.com/small2016/home/

__________

Financial Calendar for Neovacs:
April 13^th, 2016: Shareholders' AGM
October 14^th, 2016: 2016 Half-Year results

Neovacs shares are eligible for the French tax incentivized PEA-PME
Neovacs is listed on Alternext Paris - ISIN: FR0004032746

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
All information about Neovacs is available on the website: www.neovacs.fr

Contacts
Neovacs/Charlène Masson                                                                                                           
[phone]                                       
[e-mail]   
New Cap /Valentine Brouchot / Pierre Laurent
[phone]
[e-mail]

english pdf

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire

HUG#1996423